Professor Dan Chambers

Mayne Chair and Head of Mayne

Medical School (Office & AME)
Faculty of Medicine

Professor in Thoracic Med (Second)

Prince Charles Hospital Northside Clinical Unit
Faculty of Medicine


Alternate email address:

Professor Dan Chambers is a thoracic transplant physician, interstitial lung disease expert, and translational clinician researcher. He is an internationally recognised authority in the fields of lung fibrosis, cell therapy for lung disease and lung transplantation. His research focuses on the mechanisms and treatments for lung fibrosis, silicosis, transplant rejection and post-transplant complications.

Graduating from UQ in 1993 with the William Nathaniel Robertson Medal and a University Medal, Dan’s career has continued to be recognised by being named one of Australia’s top 200 researchers in all fields and the most highly cited in the field of transplantation for the last three years. Dan was the immediate past Director of the International Lung and Heart-Lung Transplant Registry, the first Australian to be appointed to that role. The Registry remains the most important source of evidence to guide the practice of transplantation globally.

Dan is Executive Director of Research at Australia’s’ largest health service, Metro North Hospital and Health, and heads one of the world’s largest clinical trials programs in lung fibrosis. He is Chair of the Pulmonary Fibrosis Australiasian Clinical Trials Network (PACT). His research program, located at UQ Thoracic Research Centre at Prince Charles Hospital, has attracted over $20 million. He has authored over 150 original papers and book chapters. He is a regular reviewer for all the highest ranked journals in respiratory and transplantation medicine and is Deputy Editor of the Journal for Heart and Lung Transplantation, the highest impact journal in the field.


MBBS(Hons1) UQ, 1993

MED University of Birmingham, UK

Research Interests

  • Lung transplantation
  • Lung fibrosis
  • Stem cells
  • Cellular therapy

Research Impacts

Professor Chambers is a recognised thought leader in the fields of lung fibrosis, lung cell therapy and lung transplantation. His contributions to these fields have translated into improvements in the management of a wide range of serious lung diseases including silicosis, lung transplant rejection, lung fibrosis and grown up neonatal lung disease. Dan pioneered the use of whole lung lavage to treat acute silicosis, work that has been featured in international media. He was a key member of the team which pioneered ex-vivo lung perfusion to resuscitate marginal donor organs in Australia in 2011. He has used this technology to improve the safety of early phase human trials, and in so doing conceived and developed guidelines for the use of donated human lungs for research in Australia, a document now endorsed by the Transplantation Society of Australia and New Zealand and utilised around the country.

His contribution to knowledge in these diverse areas has been recognised in his appointment to several governmental panels including the Biologicals Advisory Committee (Therapeutic Goods Administration, 2017-2019), the Interim Advisory Panel of the Notifiable Dust Lung Disease Register (Qld Government, 2020-2021), the Virtual Cross Match Working Group (Organ and Tissue Authority, 2020-2021) and the Registry Build Advisory Group for the National Occupational Lung Disease Registry (Australian Government Department of Health, 2020-). He has either chaired or contributed to committees and working groups which have developed international position statements or guidelines in diverse areas of advanced lung disease including the management of fungal infection, conduct of bronchoalveolar lavage, donor and recipient lung transplant management, and in the diagnosis and management of interstitial lung disease. He runs one of the world's largest clinical trial centres focussed on interstitial lung disease and has collaborated with multiple academic and industry partners to bring new treatments to patients with serious lung disease. His work is regularly featured in the Australian media.


View all Publications


View all Supervision


Featured Publications

Book Chapter

  • Chambers, Daniel C. (2018). Chronic lung allograft dysfunction: phenotypes and the future. Essentials in lung transplantation. (pp. 119-129) edited by Allan R. Glanville. Cham, Switzerland: Springer International Publishing. doi: 10.1007/978-3-319-90933-2_11

  • Chambers, Daniel (2015). Mesenchymal stromal cell-based therapies for lung disease. Stem Cells in the Lung: Development, Repair and Regeneration. (pp. 225-242) edited by Ivan Bertoncello. Heidelberg, Germany: Springer Spektrum. doi: 10.1007/978-3-319-21082-7_14

  • Chambers, D. and Hopkins, P. (2012). Pulmonary clinical applications for mesenchymal stem cells. Mesenchymal stem cell therapy. (pp. 87-99) edited by Lucas G. Chase and Mohan C. Vemuri. Totowa, NJ USA: Humana Press. doi: 10.1007/978-1-62703-200-1_5

  • Chambers, Daniel C. and Sole, Amparo (2011). Mold infections in cardiothoracic transplantation. Diagnosis and Management of Infectious Diseases in Cardiothoracic Transplantation and Mechanical Circulatory Support. (pp. 195-209) edited by Martha L. Mooney, Margaret M. Hannan, Shahid Husain and James K. Kirklin. Addison, TX, United States: International Society of Heart and Lung Transplantation.

  • Hodge, Greg, Hodge, S., reynolds, P., Chambers, D. and Holmes, M. (2009). Leucocyte intracellular cytokines in lung transplant patients : A more physiological indicator of immunosuppression than plasma drug levels. Immunosuppression : New research. (pp. 91-115) edited by Charles B. Taylor. New York, NY, United States: Nova Biomedical Books.

Journal Article

Conference Publication

Grants (Administered at UQ)

PhD and MPhil Supervision

Current Supervision

  • Doctor Philosophy — Principal Advisor

    Other advisors:

  • Doctor Philosophy — Associate Advisor

    Other advisors:

  • Doctor Philosophy — Associate Advisor

Completed Supervision